Aicardi-Goutières Syndrome (AGS)

On this page
  1. Description
  2. Signs and Symptoms
  3. Causes
  4. Laboratory Investigations
  5. Treatment and Therapies
  6. Outlook
  7. Related Disorders
  8. Resources
  9. Research
  10. References

Summary

Aicardi-Goutières Syndrome is a rare genetic disorder that causes inflammation in the brain and affects the immune system. Many children show symptoms in their first year, including developmental delays and neurological changes. However, doctors are now learning that many children develop symptoms later, after a period of normal development, or even into adulthood.

Description

AGS results from a spelling mistake in the instructions, or genes, that control how the body reacts to infections, even when no infection is present. When the body responds to infections, it makes something called interferon, special chemical cells, use to signal to other cells that an infection is present. In AGS, the body makes too much interferon, and the excessive interferon can damage cells throughout the body, but in particular the brain, liver, blood cells and skin.

There are several subtypes, which depend on the gene affected. The most common genes include TREX1, RNASEH2B, SAMHD1, ADAR1 and IFIH1. All of the different genes result in the body making too much interferon. Some patients with AGS have symptoms that cannot be linked to a specific gene but still have excessive interferon. Doctors think additional genes that cause AGS have yet to be discovered.

Signs and Symptoms

Children living with AGS might show different levels of symptoms, from mild to severe. The severe form can cause serious challenges in physical and mental development. Milder versions exist and may allow some independent skills. Often children who get sick earlier show more severe symptoms than children who get sick later in childhood.

Diagnosis involves spotting symptoms like developmental regression, feeding challenges, stiffness in muscles, and seizures. Some children experience irritability and slow growth in brain size (microcephaly).

Other signs may include:

  • Skin problems, such as red, painful lesions on fingers and toes (chilblains)
  • Unexplained fevers
  • Abnormalities in blood tests that check how the liver works
  • Low blood counts for red blood cells, white blood cells or special clotting particles called platelets

Causes

AGS develops because of genetic mutations. It is usually inherited but can also occur randomly through genetic change in just one person. These changes cause the immune system to respond as if it was fighting an infection, even in the absence of infection. Parents do not cause AGS.

Laboratory Investigations

Doctors may use:

  • MRI or CT scans to look for brain changes, such as shrinking and calcium deposits
  • Lumbar puncture to check for signs of inflammation in the fluid around the brain
  • Blood tests to check for a special type of inflammation called interferon
  • Genetic testing to confirm the diagnosis

Treatment and Therapies

There are no cures yet, but new drugs (such as Janus Kinase inhibitors) may now be able to decrease some of the symptoms related to AGS. Janus Kinase inhibitors work by blocking the ability of interferon to connect with cells in the body.

It is also important to treat symptoms to improve quality of life. Seizures can be treated with appropriate medications. Physical, occupational, and speech therapies can help maximize abilities. Patients with AGS should be seen regularly by a specialized team to help screen for health problems related to vision, hormones, swallowing, nutrition, liver problems, kidney problems, orthopedic problems and motor disabilities that can result from AGS.

Families should discuss therapy and medication choices with their healthcare team.

Outlook

Many children with AGS will need lifelong support and care. Abilities and independence can vary greatly for children with AGS, and some children with milder symptoms can achieve independence. Support from a specialized clinic can help families manage school, daily activities, health complications and developmental goals. Quality of life can improve with tailored interventions.

Resources

The links and resources included in this section are solicited directly from the community by the Child Neurology Foundation through a formal submission process. CNF reserves the right to remove entities at any time if information is deemed inappropriate or inconsistent with the mission, vision, and values of CNF. The authors listed on this page have not endorsed the resources or links provided in this section.

AGS Advocacy Association

About the AGSAA

The Aicardi Goutieres Syndrome Advocacy Association (AGSAA) is a global coalition of deeply dedicated parent advocates working alongside clinicians, researchers, and scientists. We are united in our desire to improve the lives of individuals and families living with and yet to be diagnosed with Aicardi-Goutières Syndrome using our learned experience and honoring those before us.

Our Mission: Rescuing Potential

Everything we do reflects a sense of urgency to rescue patient potential and preserve quality of life. We’re focused on accelerating research and providing timely emotional outreach and educational support alongside evolving clinical care recommendations to affected families.

United Leukodystrophy Foundation

OUR MISSION is to provide support to the leukodystrophy community and enable platforms to accelerate improving patient quality of life and finding cures.

OUR VISION is to meet the needs of patients and families, whether newly diagnosed or living with a leukodystrophy. Through unified collaboration with advocacy groups, medical and research professionals, and pharma/biotech companies, we provide support, networking, and education to help navigate the journey of the disease.

Research

ClinicalTrials.gov for AGS (birth to 17 years)

These are clinical trials that are recruiting or will be recruiting. Updates are made daily, so you are encouraged to check back frequently.

ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. This is a resource provided by the U.S. National Library of Medicine (NLM), which is an institute within the National Institutes of Health (NIH). Listing a study does not mean it has been evaluated by the U.S. Federal Government. Please read the NLM disclaimer for details.

Before participating in a study, you are encouraged to talk to your health care provider and learn about the risks and potential benefits.

For more information about participation in clinical trials, check out our education hub on the topic here.

The information in the CNF Child Neurology Disorder Directory is not intended to provide diagnosis, treatment, or medical advice and should not be considered a substitute for advice from a healthcare professional. Content provided is for informational purposes only. CNF is not responsible for actions taken based on the information included on this webpage. Please consult with a physician or other healthcare professional regarding any medical or health related diagnosis or treatment options.

References
  • MedlinePlus Genetics. Aicardi-Goutières syndrome [Internet]. Bethesda (MD): National Library of Medicine (US); 2013 [cited 2025 Sep 15]. Available from: https://medlineplus.gov/genetics/
  • Children’s Hospital of Philadelphia. Aicardi-Goutières Syndrome Overview [Internet]. Philadelphia (PA): CHOP; 2025 [cited 2025 Sep 15]. Available from: https://www.chop.edu/
  • National Organization for Rare Disorders (NORD). Aicardi-Goutières Syndrome [Internet]. Danbury (CT): NORD; 2023 [cited 2025 Sep 15]. Available from: https://rarediseases.org/
  • United Leukodystrophy Foundation. Aicardi-Goutieres Syndrome [Internet]. Sycamore (IL): United Leukodystrophy Foundation; 2020 [cited 2025 Sep 15]. Available from: https://ulf.org/
  • Hunter’s Hope Foundation. Aicardi-Goutières Syndrome (AGS) [Internet]. Orchard Park (NY): Hunter’s Hope; 2017 [cited 2025 Sep 15]. Available from: https://www.huntershope.org/
  • Orphanet. Aicardi-Goutières syndrome [Internet]. Paris (FR): INSERM; 2023 [cited 2025 Sep 15]. Available from: https://www.orpha.net/
  • Perplexity AI, Inc. Perplexity [Internet]. San Francisco (CA): Perplexity AI, Inc.; 2025 [cited 2025 Oct 24]. Available from: https://www.perplexity.ai

This overview is for general information and is not a substitute for advice from your child's care team.

← Back to the Disorder Directory